Publications by authors named "J U Reyes-Huerta"
Increasing evidence suggests a microbial pathogenesis in irritable bowel syndrome (IBS) but the relationship remains elusive. Fecal DNA samples from 120 patients with IBS, 82 Mexican (IBS-C: n = 33, IBS-D: n = 24, IBS-M: n = 25) and 38 British (IBS-C: n = 6, IBS-D: n = 27, IBS-M: n = 5), were available for analysis using 16S rRNA gene sequencing. Firmicutes (mean: 82.
View Article and Find Full Text PDFArticle Synopsis
- Irritable bowel syndrome (IBS) is a gut-brain disorder linked to changes in the gut microbiome, specifically involving the yeast Saccharomyces cerevisiae, but the significance of Anti-Saccharomyces cerevisiae antibodies (ASCA) in IBS is still unclear.
- * A study with 800 participants (400 IBS patients and 400 healthy controls) aimed to see if ASCA could differentiate IBS patients from healthy individuals by measuring ASCA IgG levels.
- * The results showed no significant difference in ASCA IgG levels between IBS patients and healthy controls, indicating that ASCA may not be a useful biomarker for IBS diagnosis or its severity.
Prevalence of methanogens and associated factors in patients with irritable bowel syndrome and healthy controls in a Southeastern Mexican population.
Rev Gastroenterol Mex (Engl Ed)
February 2023
Introduction: Methane (CH) is an inert gas produced by colonic anaerobes and has been associated with different intestinal diseases, including irritable bowel syndrome (IBS). According to geographic region, the prevalence of methanogens varies, being higher in Africa (80%) and lower in the United States (35-40%). In Mexico, the prevalence of methanogens is unknown.
View Article and Find Full Text PDFCeliac disease (CD) is a chronic immune-mediated enteropathy triggered by exposure to dietary gluten in genetically predisposed individuals. In contrast, irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder affecting the large intestine, without an autoimmune component. Here, we evaluated the prevalence of IgA and IgG antibodies to maize zeins (AZA) in patients with CD and IBS.
View Article and Find Full Text PDFIntragastric pH effect of 20mg of levo-pantoprazole versus 40mg of racemic pantoprazole the first seven days of treatment in patients with gastroesophageal reflux disease.
Rev Gastroenterol Mex (Engl Ed)
December 2020
Introduction/aim: Levo-pantoprazole, the S-enantiomer of pantoprazole, is a proton pump inhibitor that has been shown in animal studies to be faster and stronger than its racemic formulation. There are no studies on humans and therefore our aim was to evaluate the effects of levo-pantoprazole versus racemic pantoprazole on intragastric pH.
Materials And Methods: A randomized controlled study was conducted on patients with erosive gastroesophageal reflux disease that were given 20mg of levo-pantoprazole (n = 15) versus 40mg of racemic pantoprazole (n = 15) for 7 days.